EGFR and cancer: EGFR is already targeted in cancer; specifically monoclonal anti-EGFR antibodies (e.g., cetuximab) and EGFR kinase inhibitors (e.g., gefitinib) are FDA-approved to treat metastatic colorectal carcinoma [75].